West Pharmaceutical Services Inc. ($WST) Stock Forecast: Down 4.2% Today

What is West Pharmaceutical Services Inc.?

West Pharmaceutical Services (WST) specializes in packaging components and delivery systems for injectable drugs and healthcare products. The stock experienced a bearish movement today.

Why is West Pharmaceutical Services Inc. going down?

WST stock is down 4.2% on Jan 16, 2026 15:35

• Institutional investor Conning Inc. decreased its stake in AbbVie Inc., suggesting a potential shift in focus away from traditional pharmaceutical companies like AbbVie. This shift could impact related stocks such as WST.
• Analysts indicate that WST may be overvalued at its current price. Concerns about revenue headwinds and project conversion risks likely contributed to the stock's bearish movement.
• Despite positive growth prospects in the GLP-1 market and regulatory upgrades, challenges including revenue headwinds and profitability risks may have overshadowed the positive outlook, leading to the bearish market movement.
• The combination of reduced institutional investment in AbbVie, concerns about WST's overvaluation and revenue challenges, and potential risks in project conversions likely influenced the bearish movement in WST's stock today.

WST Price Chart

WST Technical Analysis

WST News

Conning Inc. Decreases Position in AbbVie Inc. $ABBV

Conning Inc. reduced its stake in AbbVie Inc. by 13.1% in the third quarter, holding 166,081 shares worth $38.45 million, making AbbVie its 6th largest holding. Despite this decrease, institutional investors collectively own 70.23% of AbbVie stock. Several analysts have issued "Buy" or "Hold" ratings with an average target price of $246.89, while AbbVie recently declared an increased quarterly dividend of $1.73 per share.

https://www.marketbeat.com/instant-alerts/filing-conning-inc-decreases-position-in-abbvie-inc-abbv-2026-01-15/

Is West Pharmaceutical Services (WST) Pricing Look Stretched After Recent Share Price Weakness

This article examines whether West Pharmaceutical Services (WST) is overvalued at its current share price of approximately US$274.98. Using a Discounted Cash Flow (DCF) analysis, the stock appears to be about 70.4% overvalued, with an estimated intrinsic value of $161.41 per share. Additionally, its current P/E ratio of 40.2x is higher than both the industry average and Simply Wall St's proprietary "Fair Ratio," further suggesting potential overvaluation.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-wst/west-pharmaceutical-services/news/is-west-pharmaceutical-services-wst-pricing-look-stretched-a/amp

Reasons to Add West Pharmaceutical Stock to Your Portfolio Now

West Pharmaceutical Services, Inc. (WST) is positioned for growth due to strong demand for GLP-1 related products and expansion initiatives, despite facing potential revenue headwinds from a contract manufacturing agreement and risks in project conversion timelines. The company's High-Value Product Components business is a key growth driver, benefiting from GLP-1 injectable therapies and Annex 1 regulatory upgrades. WST has seen positive estimate revisions for 2026, with anticipated earnings and revenue increases.

https://finviz.com/news/276605/reasons-to-add-west-pharmaceutical-stock-to-your-portfolio-now

Reasons to Add West Pharmaceutical Stock to Your Portfolio Now

West Pharmaceutical Services (WST) is poised for growth due to strong demand for its High-Value Product Components, particularly from the GLP-1 market, and tailwinds from Annex 1 regulatory upgrades. Despite these positive factors, the company faces challenges such as revenue headwinds from a major contract manufacturing agreement ending, and timing and visibility risks associated with project conversions and SmartDose 3.5 profitability. Analysts anticipate a 9.5% earnings improvement over the next five years, with positive estimate revisions for 2026.

https://www.tradingview.com/news/zacks:2de701558094b:0-reasons-to-add-west-pharmaceutical-stock-to-your-portfolio-now/

Stephens Inc. AR Boosts Position in AbbVie Inc. $ABBV

Stephens Inc. AR increased its stake in AbbVie Inc. by 4.1% in Q3, now holding 150,987 shares valued at $34.96 million. This comes as AbbVie solidifies its position through a U.S. administration agreement, strategic acquisitions, and a licensing deal with RemeGen for its oncology pipeline. Despite some near-term revenue concerns due to Medicaid price concessions, analysts have a consensus "Moderate Buy" rating with a target price of $246.89 for the company.

https://www.marketbeat.com/instant-alerts/filing-stephens-inc-ar-boosts-position-in-abbvie-inc-abbv-2026-01-14/

Trending Today

Solana ($SOL) Crypto Forecast: Down 5.8% Today

Vaulta (prev.EOS) ($A) Crypto Forecast: Down 9.5% Today

Litecoin ($LTC) Crypto Forecast: Down 6.9% Today

Sui ($SUI) Crypto Forecast: Down 11.9% Today

Cardano ($ADA) Crypto Forecast: Down 6.9% Today

Pepe ($PEPE) Crypto Forecast: Down 10.2% Today

Shiba Inu ($SHIB) Crypto Forecast: Down 6.6% Today

Dogecoin ($DOGE) Crypto Forecast: Down 7.6% Today

XRP ($XRP) Crypto Forecast: Down 5.0% Today

Dash ($DASH) Crypto Forecast: Up 10.2% Today

West Pharmaceutical Services Inc. Price History

24.06.2025 - WST Stock was up 23.7%

• WST stock surged as the company reported a strong Q2 earnings beat, driven by an increase in earnings per share due to tariff and foreign exchange benefits.
• Revenue growth in the Proprietary Products segment played a key role in the positive market movement, signaling robust demand for high-value products like GLP-1 and SmartDose.
• Investor sentiment remains upbeat about West Pharmaceutical's ability to sustain growth in Q2, buoyed by ongoing strength in critical segments.
• Bullish investor confidence today was likely strengthened by the favorable earnings outlook and segmental performance expectations for West Pharmaceutical Services, Inc.

06.05.2025 - WST Stock was up 5.5%

• The bullish movement in WST stock could be attributed to investors' optimism regarding the pending class action lawsuit.
• The reminder of the lawsuit deadline might have sparked confidence in the market, indicating that the company is taking necessary legal actions to address any potential issues.
• This proactive approach from West Pharmaceutical Services, Inc. could have reassured investors and led to increased buying interest, driving the stock price higher.
• Overall, the market's positive reaction to the news of the pending class action lawsuit reflects investor confidence in the company's ability to handle legal challenges effectively.

06.00.2026 - WST Stock was up 5.7%

• Despite executive insider selling and recent performance challenges, West Pharmaceutical Services Inc. exceeded expectations with its Q3 earnings and revenue. This likely contributed to the positive movement in the company's stock.
• The growing investments from North Growth Management Ltd. and Ethic Inc. in WST suggest increasing confidence in the company's future, especially with the optimistic FY2025 guidance provided.
• Thermo Fisher Scientific Inc. ($TMO) recently announced a quarterly dividend and a stock buyback program, potentially boosting market sentiment towards healthcare companies, including WST.
• In summary, West Pharmaceutical Services Inc.'s bullish stock movement today could be attributed to its strong financial performance, increased stake acquisitions, and positive developments in the healthcare sector.

21.10.2025 - WST Stock was up 5.1%

• The decrease in short interest indicates a positive sentiment among investors towards WST.
• The reduction in shares sold short could suggest that investors are becoming more confident in the company's future prospects.
• This decrease in short interest may have contributed to increased buying pressure on WST, leading to its bullish movement today.

16.00.2026 - WST Stock was down 4.2%

• Institutional investor Conning Inc. decreased its stake in AbbVie Inc., suggesting a potential shift in focus away from traditional pharmaceutical companies like AbbVie. This shift could impact related stocks such as WST.
• Analysts indicate that WST may be overvalued at its current price. Concerns about revenue headwinds and project conversion risks likely contributed to the stock's bearish movement.
• Despite positive growth prospects in the GLP-1 market and regulatory upgrades, challenges including revenue headwinds and profitability risks may have overshadowed the positive outlook, leading to the bearish market movement.
• The combination of reduced institutional investment in AbbVie, concerns about WST's overvaluation and revenue challenges, and potential risks in project conversions likely influenced the bearish movement in WST's stock today.

23.06.2025 - WST Stock was up 5.3%

• WST's strong bullish movement today could be attributed to the market's anticipation of steady growth in Q2 earnings, driven by the high demand for GLP-1 and SmartDose products.
• Investors may be optimistic about WST's segmental edge holding up, leading to increased confidence in the company's performance.
• The focus on innovation and meeting the demand for healthcare products could be positioning WST favorably in the market, attracting investor interest and driving the stock's upward movement.

10.06.2025 - WST Stock was up 4.0%

• The rise in WST's stock price could be due to investors' growing confidence in the company's ability to manage the class action lawsuit situation.
• Initially, the announcement of investors having the chance to lead a class action lawsuit caused uncertainty and a decrease in the stock price.
• However, as more investors engage legal support to discuss their rights before the deadline, it suggests a potential positive resolution for the company, leading to the stock's upward movement.
• This scenario emphasizes the significance of monitoring legal developments and investor sentiment alongside the company's operational performance when evaluating stock fluctuations.

04.03.2025 - WST Stock was down 6.5%

• Despite the positive surge in ProDex (PDEX) stock, WST experienced a bearish movement.
• The lack of indication for further gains in ProDex might have caused investors to reallocate their funds, leading to a sell-off in WST.
• Investors may have shifted focus from WST to ProDex, anticipating better returns based on the recent surge in PDEX stock price.
• This shift in market sentiment towards ProDex could have contributed to the bearish movement in WST as investors sought potentially more lucrative opportunities in the market.

22.03.2025 - WST Stock was up 5.4%

• WST had a strong bullish movement today due to expectations of strong segmental performance in the first quarter, driven by growth in pharmaceutical stabilization, biologics rebound, and contract manufacturing gains.
• The market is likely reacting positively to the potential growth and stability in the pharmaceutical sector, which is a key market for West Pharmaceutical Services.
• Investors are optimistic about the company's ability to capitalize on the increased demand for injectable drug administration solutions, especially in the current global health landscape.

23.09.2025 - WST Stock was up 14.5%

• The bullish movement in WST could be attributed to the anticipation of strong Q3 earnings driven by robust demand for GLP-1 and biologics products.
• Investors seem optimistic about WST's ability to navigate challenges such as labor constraints, tariffs, and plant shutdowns, which might have positively impacted the stock price.
• The market may be pricing in the potential for WST to outperform expectations despite margin pressures, showcasing confidence in the company's resilience and growth prospects.

23.09.2025 - WST Stock was up 10.7%

• WST stock experienced a bullish movement today due to the company's strong Q3 earnings beat and raised EPS outlook, driven by robust demand and favorable foreign exchange rates.
• The market responded positively to the company's solid growth in Proprietary Products, reflecting investors' confidence in West Pharmaceutical's ability to capitalize on market opportunities.
• Despite potential challenges such as labor constraints, tariffs, and plant shutdowns, the momentum in GLP-1 and biologics demand seems to have outweighed any margin pressure concerns, further boosting investor sentiment towards WST stock.

06.10.2025 - WST Stock was down 4.0%

• Analysts are bullish on WST, predicting a potential surge of 25.41% in the stock price.
• Despite positive analyst sentiment, the market may have reacted to other factors causing a bearish movement in WST.
• It is possible that external market conditions or unforeseen events impacted WST negatively, leading to the bearish trend observed today.